CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (34,512)	$ (23,694)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	93	71
Stock-based compensation	2,012	2,272
Amortization of operating lease right-of-use asset	261	237
Non-cash interest expense	2	0
Accretion on marketable securities	(270)	(159)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(165)	(864)
Other assets	(37)	190
Operating lease liability	(302)	(326)
Deferred revenue, net of deferred contract acquisition costs	(464)	(230)
Accounts payable and accrued expenses	777	748
Net cash used in operating activities	(32,605)	(21,755)
Cash flows from investing activities:
Purchases of laboratory and other equipment	(125)	(103)
Sales and maturities of marketable securities	10,000	5,498
Purchases of marketable securities	(10,757)	(18,648)
Net cash used in investing activities	(882)	(13,253)
Cash flows from financing activities:
Net proceeds from sale of common stock under Open Market Sale Agreement, net of offering costs	28,325	0
Net proceeds from sale of common stock under 2019 Employee Stock Purchase Plan	161	88
Issuance of note payable for insurance policy	1,020	0
Repayment of notes payable	(364)	0
Net cash provided by financing activities	29,142	88
Net change in cash and cash equivalents	(4,345)	(34,920)
Cash and cash equivalents at beginning of period	67,131	119,166
Cash and cash equivalents at end of period	62,786	84,246
Non-cash investing and financing activities:
Cash paid for interest	19	0
Purchases of equipment included in accounts payable and accrued liabilities	$ 8	$ 0